Viromed Medical AG: Successful Start of Trading on XETRA

Viromed Medical AG has announced a successful start of trading on XETRA, marking a significant milestone in its capital market strategy. Following its recent uplisting to the “Primärmarkt” segment of the Düsseldorf stock exchange, Viromed's shares are now available on XETRA and the Frankfurt Stock Exchange. This move is expected to broaden its investor base both domestically and internationally.

CEO Uwe Perbandt emphasized that the inclusion in XETRA trading aligns with the company’s growth prospects. Viromed aims to revolutionize medical treatments with its cold plasma technology, targeting markets worth billions. Cold atmospheric plasma has been effective in treating wounds and is being tested for pulmonary applications. Viromed believes that this technology has substantial growth potential.